Navigation Links
Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
Date:6/14/2008

MONTREAL, June 14 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.

Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on PBI-1402 in a poster entitled "PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia". Results demonstrated that a once daily oral treatment of PBI-1402 induces a significant increase in hemoglobin ("Hb") level, red blood cell ("RBC") count and hematocrit ("Ht") in CIA patients. Furthermore, results suggest that PBI-1402 can reduce the need for RBC transfusion, since only 6% of patients in the clinical trial required transfusion.

"Subsequent positive data compiled from the 28 patients having completed the PBI-1402 CIA clinical trial include the fact that 26 of these patients did not require RBC transfusions while maintaining their full chemotherapy regimen. This data further supports that PBI-1402's current performance is in line with the Food and Drug Administration's ("FDA") recommendation of reducing patient need for RBC transfusions," states Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "Additionally, PBI-1402 offers the added advantage of oral dosing which allows for a convenient management of anemia without interference with other treatments received by the CIA patients."

In the March 13, 2008 briefing document, the FDA's Oncologic Drugs Advisory Committee emphasized that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusions. Approximately 50% of anemic patients receiving chemotherapy require RBC transfusions, and 20%-25% of patients treated with ESAs still require RBC transfusions.
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. QLT announces positive Health Canada decision on Aczone(R)
3. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
4. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
6. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... GAITHERSBURG, Md. , May 28, 2015  GenVec, ... president and CEO, Douglas J. Swirsky , will ... Healthcare Conference at 11 a.m. EDT on Thursday, June ... webcast of Mr. Swirsky,s presentation will be available at ... also be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce that ... with PTI Inspection Systems. Whitehouse Labs and PTI will ... method development and validation programs using the most ... includes a more formal program that facilitates cross training ... enables a more effective team approach, especially as it ...
(Date:5/28/2015)... Georgia (PRWEB) May 28, 2015 ... National Laboratory (Oak Ridge, TN) recently signed ... of 3D printing plastic resins using nanocellulose, a ... constraint of 3D printing is the limited number ... provide inadequate mechanical strength to printed parts for ...
Breaking Biology Technology:GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an ... to be launched by,the Company into the China market. ... I tests in July 2006, which consists of tests,for ... tested in,Phases II & III. Aida is currently undergoing ...
... and DETROIT, Oct. 22 The Michigan Life,Science ... rapidly,stimulate new business for Michigan companies. (Photo: ... BioPharma Company, LLC and the Michigan Virtual,Medical Device ... exhibit during,the MichBio Expo convention in Lansing, Michigan. ...
... Highlight and ... of Advanced Practices by Leading, Interventionalists, Broadcast from Around the World. - Hear About ... Stent, Results. - See How Many of the Major Fixed Imaging and Stent Manufacturers ... are Embracing IVUS., ...
Cached Biology Technology:Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 2Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 3Virtual Life Science Companies Launch and Tour 2Virtual Life Science Companies Launch and Tour 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... contains stem cells with a surprising capacity for repair, ... journal Cell, published by Cell Press. The novel insight ... have clinical implications for the treatment of brain damage, ... mice whose brains were severely damaged by loss of ...
... they have been exposed to biological or chemical weapons could ... who are helping to develop a tiny diagnostic device that ... of a tiny pump, researchers affiliated with MIT's Institute for ... existing miniature "lab on a chip" fully portable, so the ...
... heat-loving archaeon capable of fixing nitrogen at a surprisingly ... Earth’s earliest lineages of organisms capable of nitrogen fixation, ... and animals rely on to fix nitrogen. , ... of Science supports the notion that the gene needed ...
Cached Biology News:Neural stem cells lend the brain a surprising capacity for self-repair 2MIT designs portable 'lab on a chip' 2MIT designs portable 'lab on a chip' 3Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
... ZMD.440. Immunogen: Synthetic peptide derived from ... (platelet derived growth factor D iris-expressed growth ... differs from mouse and rat by one ... the ~50 kDa human mouse and rat ...
...
...
...
Biology Products: